Neofact® - Medical device for surfactant application
Product Description
Lyomark Pharma GmbH
-
Country/Region:Germany
-
On CPHI since:2015
Company types
Categories
Specifications
Lyomark Pharma GmbH
-
Country/Region:Germany
-
On CPHI since:2015
Company types
More Products from Lyomark Pharma GmbH (2)
-
Product Alveofact® - Natural bovine lung surfactant
Alveofact is used in neonates. Preventive use in premature neonates with a high risk of respiratory distress syndrome (RDS).
Active substance: Phospholipid fractionfrom bovine lung (surfactant) -
Product Neofact - Clinical evaluation of an application aid for less-invasive surfactant administration (LISA)
Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS.
This study shows that the LISA method (less invasive surfactant administration) via Neofact® appears feasible.
Neofact® makes surfactant application easy and is also suitable for all gesta...
Lyomark Pharma GmbH resources (1)
-
Datasheet Neofact® - Feasibility study
In the clinical study carried out at the University Hospital Tübingen, 20 premature infants (gestational age ≥26 + 0/7) were administered surfactant Alveofact® (45 mg / mL; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid Neofact®. The aim of developing Neofact® was to enable a simple and gentle process for surfactant application that works without the use of Magill forceps. Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing. An extremely high success rate could be achieved (95%), complications seemed rear.
Further information on the study can be found: https://pubmed.ncbi.nlm.nih.gov/33023914/